苯达莫司汀联合利妥昔单抗治疗脾边缘区淋巴瘤的疗效:BRISMA/IELSG36 II期研究结果
BRISMA/IELSG36是一项开放标签、单臂II期研究,采用Simon两阶段设计,纳入56例经中心复核确诊的脾边缘区淋巴瘤患者,接受苯达莫司汀联合利妥昔单抗一线治疗6个周期。总缓解率91%,完全缓解率73%,3年缓解持续时间93%、无进展生存率90%、总生存率96%;毒性以血液学为主。
要点
- 苯达莫司汀联合利妥昔单抗一线治疗脾边缘区淋巴瘤总缓解率91%、完全缓解率73%。
- 3年缓解持续时间93%、无进展生存率90%、总生存率96%。
- ≥3级中性粒细胞减少43%,感染5.4%,发热性中性粒细胞减少3.6%。
核心结论
- 苯达莫司汀联合利妥昔单抗是脾边缘区淋巴瘤非常有效的一线方案。
- 基于BRISMA研究结果,当症状性脾边缘区淋巴瘤患者被认为需要含利妥昔单抗的化疗联合方案时,应考虑苯达莫司汀联合利妥昔单抗。
研究设计与样本
- BRISMA/IELSG36是一项开放标签、单臂II期研究,由IELSG与Fondazione Italiana Linfomi及淋巴瘤研究协会合作设计,采用Simon两阶段法。
- 共56例经中心复核确诊的脾边缘区淋巴瘤患者接受苯达莫司汀(90 mg/m2,第1、2天)联合利妥昔单抗(375 mg/m2,第1天)治疗,每28天一个周期,共6个周期。
- 主要终点为完全缓解率。
主要发现
- 总缓解率为91%,完全缓解率为73%。
- 3年缓解持续时间为93%(95%CI 81-98),3年无进展生存率为90%(95%CI 77-96),3年总生存率为96%(95%CI 84-98)。
- 毒性以血液学为主,≥3级中性粒细胞减少发生率为43%,感染发生率为5.4%,发热性中性粒细胞减少发生率为3.6%。
- 共14例患者(25%)发生严重不良事件。
- 5例患者(9%)因毒性退出研究,1例患者死于感染。
临床怎么用
- 基于BRISMA研究结果,作者认为当症状性脾边缘区淋巴瘤患者需要含利妥昔单抗的化疗联合方案时,应考虑苯达莫司汀联合利妥昔单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91% and 73%, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93% (95% confidence interval [CI] 81-98), 90% (95% CI 77-96) and 96% (95% CI 84-98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43% of patients; infections and febrile neutropenia in 5·4% and 3·6%. Overall, 14 patients (25%) experienced serious adverse events. Five patients (9%) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.
引用
- Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018. PMID: 30407629. doi:10.1111/bjh.15641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。